PTGX: Strong drug approvals, innovative oral peptide pipeline, and strategic partnerships drive growth
Two drugs were approved this year, including MIMRYLO for PV, with strong commercial launches and robust pharma partnerships driving revenue and R&D. The pipeline focuses on oral peptide therapeutics targeting chronic diseases, with strategic plans for asset retention, partnerships, and early clinic…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.